Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Silexion Therapeutics Corp - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
SLXN
Nasdaq
2830
silexion.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Silexion Therapeutics Corp
Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Nov 13th, 2026 7:04 am
Silexion Therapeutics Announces 1-for-24 Reverse Share Split
- Nov 9th, 2026 5:00 am
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
- Sep 30th, 2026 6:00 am
Silexion Therapeutics Announces Exercise of Warrants
- Sep 29th, 2026 6:03 am
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
- Sep 28th, 2026 6:30 am
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
- Sep 9th, 2026 7:00 am
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Aug 14th, 2026 6:45 am
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
- Aug 11th, 2026 6:01 pm
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
- Aug 4th, 2026 7:15 am
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
- Jul 29th, 2026 5:00 am
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
- Jun 23rd, 2026 6:40 am
Silexion Therapeutics to Attend BIO International Convention 2026
- Jun 16th, 2026 2:30 pm
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
- May 26th, 2026 6:30 am
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- May 18th, 2026 6:30 am
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
- May 15th, 2026 6:27 am
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
- May 14th, 2026 7:27 am
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
- May 13th, 2026 6:00 am
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
- Apr 28th, 2026 6:45 am
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
- Mar 24th, 2026 7:46 am
Scroll